StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Sarepta Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Sarepta Therapeutics's gross margin for the twelve months ending Dec 31, 2025 was 98.8%. For fiscal 2025 it was 98.8%, against 97.6% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202598.8%+1.2
FY2016Dec 31, 201697.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-6.6%−83.4
Q3 FY2025Sep 30, 202554.9%−17.5
Q2 FY2025Jun 30, 202559.0%−28.1
Q1 FY2025Mar 31, 202563.6%−11.1
Q4 FY2024Dec 31, 202476.8%−21.6
Q3 FY2024Sep 30, 202472.4%−26.1
Q2 FY2024Jun 30, 202487.1%−10.5
Q1 FY2024Mar 31, 202474.7%–
Q2 FY2017Jun 30, 201798.5%–
Q1 FY2017Mar 31, 201798.5%–
Q4 FY2016Dec 31, 201697.6%–

More Sarepta Therapeutics figures

See a number that looks wrong?